It will be crucial to evaluate whether the iRGD-induced tumour-blood transport occurs in patients with HCC and other tumours as revealed by changes in the blood levels of tumour-derived markers such as the clinical tumour markers AFP and PSA or emerging tumour markers. This evidence concerns the gene AFP and neoplasm.